Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma (Q66047046)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma |
clinical trial |
Statements
A Phase II Investigator Sponsored Multi-Centre Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma (English)
0 references
8 July 2016
0 references
January 2020
0 references
21
0 references
21 year
0 references
99 year
0 references